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1. Introduction 
1,2,4-Oxadiazoles have attracted attention due to their 
biological activity, often related to their bioisosteric nature and 
use in medicinal chemistry.1 This area has been extensively 
reviewed1 and a selection of recent compounds of interest is 
shown in Figure 1. Compound 1 is one of a series of 1,2,4-
oxadiazoles that are potent EthR inhibitors that boost 
ethionamide activity in the treatment of multi-drug resistant 
tuberculosis.2 Compound 2 is of interest as a combretastatin A-4 
analogue with higher efficacy as an antimitotic agent.3 Thiol 
linked 1,2,4-oxadiazoles 3 that have electron withdrawing aryl 
substituents show great potency towards androgen independent 
prostrate cancer cell-lines.4 Compound 4 is an excellent in vivo 
sphingosine phosphate receptor-1 (S1P1) selective modulator that 
suppresses the development of autoimmune diseases including 
multiple sclerosis and adjuvant-induced arthritis models.5 
Compound 5 is representative of a potent class of tankyrase 
(TNKS1/2) dual inhibitors that show no activity at poly(ADP-
ribose) polymerase (PARP1 and 2) domains, and are inhibitors of 
the Wnt pathway whose dysregulation is a key priority in 
multiple diseases including several cancers.6 In 2011 the first 
1,2,4-oxadiazole natural products, phidianidines A (6, X = Br) 
and B (6, X = H), were isolated7a – from a marine opisthobranch 
source – and their synthesis reported shortly thereafter.7b 1,2,4-
Oxadiazoles are also of interest in materials research1 with recent 
examples including bent-core8 and bent-rod liquid crystals9 with 
stable liquid phases over broad temperature ranges. 3-Nitro-5-
substituted-1,2,4-oxadiazoles such as compound 7 are reported as 
“explosophoric” energetic, insensitive high explosives.10 Finally, 
the use of pyridyl-1,2,4-oxadiazoles11 and bis-1,2,4-oxadiazole12 
as ligands that chelate NiII, CuII, ZnII and PdII has been reported, 
together with a report that bis(pyridyl)-1,2,4-oxadiazole CuII 
complexes display promising activity as DNA groove binders.13 
 
Figure 1: A selection of 1,2,4-oxadiazoles of recent interest 
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1,3-Dipolar cycloaddition of nitrile oxides to 4-aryl-2-alkylthio-1-azetines gave a series of 
oxadiazabicyclo[3.2.0]heptenes as single diastereoisomers. Heating these cycloadducts in
toluene resulted in an overall [2+2]-cycloreversion to give 5-alkylthio-3-aryl-1,2,4-oxadiazoles. 
In this process, the 1-azetine behaves as a thiocyanate equivalent. When the nitrile oxide 
substituent was 2-azidobenzene, the azide could be converted into a 1,2,3-triazole giving a 
(1,2,4-oxadiazolo)-(1,2,3-triazolo)-1,2-disubstituted benzene. 1,2,4-Oxadiazoles are sought after 
in medicinal chemistry and materials sciences.  
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1,2,4-Oxadiazoles are most commonly constructed using 1,3-
dipolar cycloadditions between nitrile oxides and nitriles1,14 or 
from the reactions of a nitrile-derived amidoxime with a 
carboxylic acid derivative.1,15 In this report, we show that 5-
alkylthio-1,2,4-oxadiazoles 10 can be obtained from a formal 
[2+2]-cycloreversion of the oxadiazabicyclo[3.2.0]heptenes 9 
[Scheme 1] which in turn are readily constructed from the 1,3-
dipolar cycloaddition of a nitrile oxide to a 4-aryl-1-azetine 8. In 
this process, the 1-azetine acts as an equivalent for the nitrile 
species R1S–CN, known as either an alkyl thiocyanate or an alkyl 
thiocyanic ester.16 
 
Scheme 1: Synthesis of 1,2,4-oxadiazoles from 1-azetines 
  
2. Results and Discussion 
This work has its origins in our studies [Scheme 2] that 
focused upon the synthesis of azabicycles 13 from the reaction of 
cyclic imines 11 with cyclopropenones 12, where the latter 
function as all-carbon 1,3-dipole equivalents 14.17 When the 
imine 11 was a 4-aryl-1-azetine the intermediate bicycles 13a (n 
= 1) gave the tetra-substituted pyridines 16.18 We postulated that 
this transformation proceeded through a [2+2] cycloreversion to 
give a non-isolable, high-energy azacyclopentadienone 15 and a 
styrene. The styrene and intermediate 15 then recombine by 
Diels-Alder reaction, followed by chelotropic extrusion of carbon 
monoxide and aromatisation to yield the pyridine, paralleling the 
synthesis of benzenes from cyclopentadienones. The ease with 
which this process produced the proposed intermediate 15 led us 
look at this as a route for the formation of 1,2,4-oxadiazoles, 
which we anticipated would be isolable and not undergo further 
reaction.  
 
Scheme 2: Pyridines from azacyclopentadienones19 
 
As shown in Scheme 3 and Table 1, the 1-azetines 8 required 
for this study were synthesised from the alkylation of the 
corresponding thio-β-lactams 18 with Meerwein’s salts or 
dimethyl sulfate. The thio-β-lactams were obtained from the 
reaction of the β-lactam 17 with either Lawesson’s reagent,19 or 
the much more convenient and odour-free P4S10-pyridine 
complex developed by Bergman.20 The β-lactams 17 were easily 
available from the reaction of chlorosulfonyl isocyanate (CSI) 
with the relevant styrene.21 The nitrile oxides were generated by 
the standard route22 of dehydrochlorination of the chloro-oximes 
19. This approach produced seven examples, 9a – c and 9e – h, 
of the desired oxadiazabicycles 9 as summarised in Table 1. As 
seen in Table 1, the oxadiaza[3.2.0]bicycles 9 were produced in 
yields of 43 – 72%. It is worth noting that each of the adducts 9 
was a single diastereoisomer with (nOesy) cis stereochemistry 
between the Ar1 and SR1 groups, presumably a result of the 
incoming 1,3-dipole approaching trans to the existing Ar1 group, 
thus forcing the SR1 group cis to the Ar1 substituent. The 
treatment of the azido compound 9a (Ar2 = 2-N3-C6H4) with 
triphenylphosphine followed by hydrolysis gave the 
corresponding amino species 9d (Ar2 = 2-NH2-C6H4) in 70% 
overall yield, giving us access to an eighth example of an 
oxadiaza[3.2.0]bicycle. 
When heated to reflux in toluene, all but one of the 
oxadiazabicycles 9a-h formed the 5-alkylthio-1,2,4-oxadiazole 
10 (Scheme 3), in good to excellent yields (see Table 1). The one 
exception was compound 9d which proved to be stable, possibly 
as a result of increased stability resulting from intramolecular 
hydrogen bonding between the amino group and N-2 or N-4 of 
the oxadiazolidine ring (as shown for N-2 in Scheme 3). The 
products of these reactions, 5-alkylthio-1,2,4-oxadiazoles 10, are 
a class of 1,2,4-oxadiazole that have attracted no other synthetic 
approaches to our knowledge.1 We are currently exploring the 
synthetic utility of the 5-alkylthio-1,2,4-oxadiazoles 10. 
 
Scheme 3: The synthesis of 5-alkylthio-1,2,4-oxadiazoles 10 
 
A further example of a 5-alkylthio-1,2,4-oxadiazole, the 
aryltriazole compound 10i (Scheme 4), was obtained by reacting 
the azido compound 9a with dimethylacetylene dicarboxylate 
(DMAD) in toluene for 20 hours at reflux. The product 
presumably forms through consecutive [2+2]-cycloreversion and 
azide 1,3-dipolar cycloaddition. The presumed intermediate of 
the cycloaddition-first pathway (Pathway A, Scheme 4), 
compound 9i, could not be detected, whereas TLC indicated that 
the 1,2,4-oxadiazole 10a was present in small amounts, implying 
that the cycloreversion-first pathway (Pathway B, Scheme 4) 
represents the correct sequence of events. Compound 10i could 
be obtained in 65% yield by treating 1,2,4-oxadiazole 10a with 
DMAD in toluene for 4 hours at reflux confirming that it can act 
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as a credible precursor for the formation of 1,2,4-oxadiazole 10i. 
 
 
Scheme 4: Routes to the 3-(triazoloaryl)-1,2,4-oxadiazole 10i 
 
3. Conclusions 
 
1,3-Dipolar cycloadditions of nitrile oxides to 4-aryl-2-
alkylthio-1-azetines gave oxadiazabicyclo[3.2.0]heptenes that 
underwent a formal [2+2]-cycloreversion and loss of a styrene to 
furnish 5-alkylthio-3-aryl-1,2,4-oxadiazoles. The use of 2-azido-
benzonitrile oxide allowed subsequent 1,3-dipolar cycloaddition 
of DMAD to the azide (“click” reaction) in order to furnish the 1-
(1,2,4-oxadiazolo)-2-(1,2,3-triazolo)-substituted benzenes 10i. In 
these processes, a 2-alkylthio-1-azetine functions as an 
equivalent of the alkyl thiocyanate or alkyl thiocyanic ester 
functional group. We are currently exploring the properties and 
synthetic utility of the 5-alkylthio-1,2,4-oxadiazoles 10, and are 
also extending our studies to look at other nitrilium betaines and 
other 1-azetines. As part of a recently initiated programme of 
study23 focused upon 1,2,4-oxadiazoles as ligands in 
supramolecular coordination chemistry, we are also exploring the 
ligand properties of compound 10i. 
 
Table 1. 1-Azetines 8, oxadiaza[3.2.0]bicycles 9 and 1,2,4-oxadiazoles 10 produced as per Scheme 3 
Entry Ar1 Yield of 17 (%) Yield of 18 (%) Yield of  8 (%) R1 Ar2 Yield of  9 (%) Yield of 10 (%) 
a Ph 75 – 77a 63 – 86a 46 – 61a Et 2-N3-C6H4 63 51 
b 2-Naphth 64 73 40 Me 2-N3-C6H4 44 68 
c Ph 75 – 77a 63 – 86a 46 – 61a Et Ph 60 83 
d Ph -b -b -b Et 2-NH2-C6H4 70b -c
e Ph 75 – 77a 63 – 86a 43 Me 4-MeO-C6H4 43 88 
f 4-Me-C6H4 83 82 41 Me 4-MeO-C6H4 72 82 
g 4-Me-C6H4 83 82 39 Et 4-MeO-C6H4 48 81 
h 2-Naphth 64 73 40 Me 4-MeO-C6H4 44 87 
i -d -d -d -d Et See Scheme 4 Not formedd 41d 
aThe sequence of reactions leading to 1-azetine 8a (R1 = Et, Ar1 = Ph) was performed more than once, hence giving a range of yields.  bProduced by Staudinger 
reaction and subsequent hydrolysis of compound 9a.  c The adduct 9d was stable.  dCompound 10i  was formed directly from compound 9a – see Scheme 4. 
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4. Experimental Section 
 
All reactions were conducted using oven-dried glassware 
under nitrogen dried through 4 Å molecular sieves and delivered 
through a gas manifold. Work-up procedures were carried out in 
air. All solvents were purchased from Fisher Chemicals and were 
of analytical grade. Anhydrous grade solvents were freshly 
distilled using a continuous still under nitrogen. Acetone was 
dried overnight over 3 Å molecular sieves (10% w/v), and then 
distilled over freshly activated 3 Ǻ molecular sieves over 3-4 h. 
Chloroform was dried over 4 Å molecular sieves or distilled over 
phosphorus pentoxide (3% w/v). Dichloromethane, ethyl acetate 
and toluene were distilled over calcium hydride (5% w/v) over 4-
6 h. Diethyl ether and THF were pre-dried over sodium wire, and 
then distilled over sodium wire (1-2% w/v) with benzophenone 
(0.2-0.3% w/v) as an indicator. Any other anhydrous solvents 
were purchased from Acros or Sigma-Aldrich. All reactions were 
monitored by TLC, which was carried out on 0.20 mm 
Macherey-Nagel Alugram® Sil G/UV254 silica gel-60 F254 
precoated aluminium plates and visualisation was achieved using 
UV light and / or vanillin stain. Column chromatography was 
performed on Merck silica gel (0.063-0.200 mm, 60 Å). NMR 
spectra were recorded on a Bruker DPX-400 instrument or on a 
Bruker Avance 500. IR spectra were recorded on a Nicolet 380 
FT-IR instrument as a thin film for oils, a drop for liquids or neat 
for solids. Mass spectra were recorded on a Bruker Daltonics 
micrOTOF mass spectrometer operating at a positive ion mode 
under an electrospray ionisation (ESI +) method. High resolution 
mass spectra were recorded on a Finnegan MAT 900 XTL 
instrument operated by the EPSRC National Mass Spectrometry 
service at the University of Swansea. Melting points were 
recorded on a Gallenkamp apparatus. 1-Azetines 8a-h were 
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synthesised as reported previously,18 and gave consistent 
spectroscopic data. 
 
4.1. 2-(2-Azidophenyl)-5-ethylthio-7-phenyl-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9a 
To 2-ethylthio-4-phenyl-1-azetine (8a)18 (176 mg, 0.920 
mmol) and 2-azidobenzohydroximoyl chloride24 (19a) (181 mg, 
0.921 mmol) was added triethylamine (0.153 mL, 112 mg, 1.10 
mmol) diluted in diethyl ether (5 mL) dropwise over 5 hours at 
room temperature. The mixture was stirred overnight under an 
inert atmosphere. The solution was filtered and the solvent was 
removed in vacuo to give the crude product as an orange oil 
which was purified by gravity silica chromatography (Rf = 0.3; 
PE 40-60 ºC / EtOAc: 9/1) to give the product as a single 
diastereoisomer as a yellow oil (206 mg, 63%). 
IR υmax (cm-1) 2928 (w), 2114 (s), 1683 (m), 1592 (m), 1577 
(m), 1498 (m), 1455 (m), 1293 (m), 1164 (m), 1090 (m), 1054 
(m), 749 (s), 698 (s). 
1H NMR: δ (400 MHz, CDCl3) 7.57 (2H, d, J=7.1 Hz, Ph), 
7.43-7.33 (5H, m, Ph), 7.24 (1H, d, J=7.4 Hz, Ph), 6.87 (1H, t, 
J=7.6 Hz, Ph), 4.81 (1H, dd, J=9.3 and 5.4 Hz, PhCHN), 3.69 
(1H, dd, J=13.1 and 9.3 Hz, PhCHCH2), 2.86 (1H, dq, J=12.6 
and 7.5 Hz, SCH2CH3), 2.75 (1H, dq, J=12.6 and 7.5 Hz, 
SCH2CH3), 2.72 (1H, dd, J=13.1 and 5.4 Hz, PhCHCH2), 1.36 
(3H, t, J=7.5 Hz, SCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 158.6 (N-C=N), 140.5 (C, Ar), 
138.8 (C, Ar), 131.7 (CH, Ar), 131.6 (C, Ar), 130.8 (CH, Ar), 
128.6 (CH, Ar), 128.0 (CH, Ar), 126.1 (CH, Ar), 124.6 (CH, Ar), 
119.4 (CH, Ar), 110.9 (C-SEt), 66.8 (CH), 45.2 (SCH2CH3), 22.5 
(CH2), 14.6 (SCH2CH3). 
MS (m/z) 352.1 [M+H]+, 374.1 [M+Na]+, 725.2 [M2 + Na]+. 
HRMS (m/z) [M]+ for C18H17N5OS calculated 351.1148 
measured 351.1145. 
4.2. 2-(2-Azidophenyl)-5-methylthio-7-(2'-naphthyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9b 
Obtained as per the method for compound 9a as a clear yellow 
oil (74 mg, 44%) from 2-methylthio-4-(2'-naphthyl)-1-azetine 
(8b)18 (100 mg, 0.440 mmol) and 2-azidobenzohydroximoyl 
chloride (19a) (100 mg, 0.509 mmol); Rf = 0.3 (PE 40-60  ºC / 
EtOAc: 10/1).  
IR υmax (cm-1) 2968 (m), 2918 (m), 2128 (s), 1597 (m), 1581 
(m), 1447 (m), 1300 (m), 751 (m). 
1H NMR:  (500 MHz, CDCl3) 7.95-7.85 (2H, m, Ar), 7.82 
(1H, dd, J=7.0 and 1.5 Hz, Ar), 7.58-7.50 (2H, m, Ar), 7.44-7.38 
(2H, m, Ar), 7.28-7.23 (2H, m, Ar), 7.18 (1H, d, J=8.0 Hz, Ar), 
6.96 (1H, td,  J=1.0 and 7.0 Hz, Ar), 5.01 (1H, dd, J=9.3 and 5.5 
Hz, ArCHN), 3.74 (1H, dd, J=13.0 and 9.3  Hz, ArCHCH2), 2.82 
(1H, dd, J=13.0 and 5.5 Hz, ArCHCH2) 2.3 (3H, s, SCH3). 
13C NMR  (125 MHz, CDCl3) 158.8 (N=C-N), 139.1 (C, Ar), 
137.9, (C, Ar), 133.2 (C, Ar), 132.2 (C, Ar), 132.0 (CH, Ar), 
131.0 (CH, Ar), 130.2 (CH, Ar), 128.9 (CH, Ar), 128.4 (CH, Ar), 
128.0 (CH, Ar), 126.4 (CH, Ar), 126.3 (CH, Ar), 124.8 (CH, Ar), 
124.0 (CH, Ar), 119.6 (CH, Ar), 118.8 (C, Ar), 116.1 (C-SMe), 
66.8 (CH), 22.7 (CH2), 10.8 (CH3).  
HRMS (m/z) [M + Na]+ for C21H17N5NaOS calculated 
410.1046, measured 410.1046.  
4.3. 2,7-Diphenyl-5-ethylthio-4,1,3-oxadiazabicyclo[3.2.0]hept-
2-ene 9c 
Obtained as per the method for compound 9a as a clear yellow 
oil (197 mg, 60%) from 2-ethylthio-4-phenyl-1-azetine (8a)18 
(200 mg, 1.05 mmol) and benzohydroximoyl chloride (19c) (160 
mg, 1.05 mmol); Rf = 0.3 (PE 40-60  ºC / EtOAc: 10/1). 
IR υmax (cm-1) 3054 (w), 1592 (m), 1421.9 (m), 1265.3 (s), 
1167 (m), 1092 (m), 1060 (m), 750 (s), 701 (s) .            
1H NMR: δ (400 MHz, CDCl3) 7.50-7.46 (6H, m, Ar-H), 7.44-
7.40 (4H, m, Ar-H), 4.85 (1H, dd, J = 9.2, 5.4 Hz, CHPh), 3.72 – 
3.68 (1H, m, PhCHCH2), 2.89 (1H, dq, J=12.6, 7.8 Hz, SCH2), 
2.78-2.76 (2H, m, 1×SCH2 + 1×PhCHCH2), 1.37 (3H, t, J = 7.8 
Hz, CH3).        
13C NMR δ (100 MHz, CDCl3) 192.2 (C=N), 160.7 (C, Ar), 
156.1 (C, Ar), 140.5 (Ar, CH), 130.9 (Ar, CH), 128.9 (Ar, CH), 
128.8 (Ar, CH), 128.7 (Ar, CH), 128.1 (Ar, CH), 117.2 (C-SEt), 
66.7 (CH), 45.4 (CH2), 22.5 (CH2), 14.7 (CH3).     
HRMS (m/z) [M+H]+ calculated for C18H19N2OS 311.1213, 
measured = 311.1214.             
4.4. 2-(2'-Aminophenyl)-5-ethylthio-7-phenyl-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9d 
2-(2’-Azidophenyl)-5-(ethylthio)-7-phenyl-4-oxa-1,3-
diazabicyclo[3.2.0]-hept-2-ene 9a (0.0468 g, 0.133 mmol) and 
triphenylphosphine (0.039 g, 0.149 mmol), were dissolved in 
tetrahydrofuran (5 mL) and stirred for 24 hours at room 
temperature under an atmosphere of nitrogen.  Water (0.250 mL) 
was then added in one portion and the reaction was heated at 
reflux for a further 24 hours.  The sample was concentrated under 
vacuum purified by silica column chromatography (eluent: 
petroleum ether: ethyl acetate, 6:1) to yield the amine (9d; 0.030 
g, 70% yield) as a yellow oil; Rf = 0.3 (PE 40-60  ºC / EtOAc: 
10/1).         
IR υmax (cm-1) 3448 (m, broad), 2977 (m), 2847 (m), 1593 (s), 
1412 (m), 1390 (m), 1302 (m), 1178 (m).             
1H NMR δ (500 MHz, CDCl3) 7.50 – 7.60 (2H, m, Ar-H), 
7.38 – 7.32 (2H, m, Ar-H), 7.31 – 7.28 (1H, m, Ar-H), 7.01 – 
7.13 (1H, m, Ar-H), 6.89 (1H, dd, J=5.0, 1.0 Hz, Ar-H), 6.63 
(1H, dd, J=8.1, 1.0 Hz, Ar-H), 6.31 – 6.42 (1H, m, Ar-H), 5.39 
(2H, s, NH2), 4.75 (1H, dd, J=10.0, 5.0 Hz, PhCH), 3.55 – 3.59 
(1H, m, PhCHCH2), 2.74 – 2.78 (1H, m, PhCHCH2), 2.71 – 2.63 
(2H, m, CH3CH2), 1.27 (3H, t, J=7.5 Hz, CH3).                          
13C NMR δ (125 MHz, CDCl3) 161.9 (C=N), 147.1 (Ar, C), 
140.7 (Ar, C), 131.6 (Ar, CH), 129.7 (Ar, CH), 128.8 (Ar, CH), 
128.4 (Ar, CH), 126.7 (Ar, CH), 116.6 (Ar, CH), 115.7 (Ar, CH), 
110.0 (Ar, C), 106.9 (CSEt), 67.4 (CH), 45.2 (CH2), 29.7 (CH2), 
14.8 (CH3).     
HRMS (m/z) [M]+ for C18H19N3OS calculated = 325.1243, 
measured = 325.1245. 
4.5. 2-(4'-Methoxyphenyl)-5-methylthio-7-phenyl-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9e 
Obtained as per the method for compound 9a as a clear yellow 
oil (140 mg, 43%) from 2-methylthio-4-phenyl-1-azetine (8e)18 
(180 mg, 0.984 mmol) and 4-methoxybenzohydroximoyl 
chloride (19e) (182 mg, 0.981 mmol); Rf = 0.3 (PE 40-60  ºC / 
EtOAc: 10/1). 
IR υmax (cm-1) 2905 (w), 1606 (s) 1510 (s), 1421 (m), 1347 
(m), 1305 (m), 1256 (s), 1172 (m), 1026 (m), 836 (m), 753 (m). 
1H NMR:  (500 MHz, CDCl3) 7.64-7.38 (5H, m, Ph), 6.97 
(2H, d,  J=7.0 Hz, Ar), 6.82 (2H, d, J=7.0 Hz, Ar), 4.83 (1H, dd, 
J=5.5, 9.3 Hz, PhCH), 3.82 (3H, s, OCH3), 3.67 (1H, dd,  J=9.3, 
 5
13.0 Hz, PhCHCH2), 2.72 (1H, dd, J=13.0 and 5.5 Hz, 
PhCHCH2), 2.17 (3H, s, SCH3). 
13C NMR  (125 MHz, CDCl3) 161.7 (N=C-N), 160.6 (C, Ar), 
140.6 (C, Ar), 137.5 (C, Ar), 133.9 (CH, Ar), 128.7 (CH, Ar), 
128.6 (CH, Ar), 126.9 (CH, Ar), 114.6 (CH, Ar), 114.4 (C-SMe), 
66.5 (CH), 55.3 (OCH3), 44.6 (CH2), 10.3 (SCH3). 
MS (m/z) 349.1 [M+Na]+, 675.2 [M2 + Na]+. 
HRMS (m/z) [M+Na]+ for C18H18N2NaO2S calculated = 
349.0164, measured = 349.0159. 
4.6. 2-(4'-Methoxyphenyl)-5-methylthio-7-(4'-tolyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9f 
Obtained as per the method for compound 9a as a clear yellow 
oil (140 mg, 72%) from 2-methylthio-4-(4'-tolyl)-1-azetine (8f)18 
(110 mg, 0.571 mmol) and 4-methoxybenzohydroximoyl 
chloride (19e) (107 mg, 0.574 mmol); Rf = 0.3 (PE 40-60  ºC / 
EtOAc: 10/1). 
IR υmax (cm-1) 2893 (w), 1608 (s) 1512 (s), 1346 (s), 1306 (m), 
1255 (s), 1172 (s), 1051 (m), 1031 (m), 838 (m), 753 (m). 
1H NMR:  (500 MHz, CDCl3) 7.42-7.39 (4H, m, 2 × Ar1, 2 × 
Ar2), 7.14 (2H, d, J=8.0 Hz, Ar1), 6.71 (2H, d, J=7.2 Hz, Ar2), 
4.68 (1H, dd, J=5.4 and 9.4 Hz, Ar1CH), 3.68 (3H, s, OCH3), 
3.54 (1H, dd, J=9.4 and 13.3 Hz, Ar1CHCH2), 2.61 (1H, dd, 
J=5.4 and 13.3 Hz, Ar1CHCH2), 2.30 (3H, s, SCH3), 2.13 (3H, s, 
CH3). 
13C NMR  (125 MHz, CDCl3) 161.8 (N=C-N), 160.7 (C, Ar), 
138.1 (C, Ar), 137.9 (C, Ar), 129.1 (CH, Ar), 128.7 (CH, Ar), 
126.4 (CH, Ar), 116.9 (C, Ar), 114.7 (CH, Ar), 111.2 (C-SMe), 
66.5 (CH), 55.4 (OCH3), 44.7 (CH2), 21.1 (ArCH3), 10.4 (SCH3).   
MS (m/z) 341.1 [M+H+], 363.1 [M+Na]+. 
HRMS (m/z) [M+H]+ for C19H21N2O2S calculated = 341.0501, 
measured = 341.0503. 
4.7. 2-(4'-Methoxyphenyl)-5-ethylthio-7-(4'-tolyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9g 
Obtained as per the method for compound 9a as a clear yellow 
oil (83 mg, 48%) from 2-ethylthio-4-(4'-tolyl)-1-azetine (8g)18 
(100 mg, 0.485 mmol) and 4-methoxybenzohydroximoyl 
chloride (19e) (100 mg, 0.539 mmol); Rf = 0.3 (PE 40-60  ºC / 
EtOAc: 10/1). 
IR υmax (cm-1) 2915 (w), 1608 (s), 1590 (m), 1512 (s), 1345 
(m), 1256 (s), 1173 (m), 1030 (m), 838 (m). 
1H NMR:  (500 MHz, CDCl3) 7.54-7.49 (2H, m, ArH), 7.29-
7.24 (2H, m, ArH), 6.95 (2H, dd,  J=2.4 and 8.1 Hz, ArH), 6.83 
(2H, d, J=7.2 Hz, ArH), 4.80 (1H, dd, J=5.3 and 9.3 Hz, ArCH), 
3.8 (3H, s, OCH3), 3.62 (1H, dd,  J=9.3 and 13.0 Hz, ArCHCH2), 
2.92-2.75 (2H, m, SCH2CH3), 2.71 (1H, dd, J=5.3 and 13.0 Hz, 
ArCHCH2), 2.42 (3H, s, Ar-CH3), 1.36 (3H, t, J=7.0, SCH2CH3). 
13C NMR:  (125 MHz, CDCl3) 161.8 (N=C-N), 160.7 (C, 
Ar), 138.0 (C, Ar), 137.8 (C, Ar), 129.4 (CH, Ar), 129.0 (CH, 
Ar), 126.4 (C, Ar), 114.4 (CH, Ar), 114.2 (CH, Ar), 111.5 (C, 
CSEt), 66.77 (CH), 55.3 (OCH3), 45.4 (ArCHCH2), 22.7 (SCH2), 
21.1 (ArCH3), 14.8 (SCH2CH3). 
MS (m/z) 377.1 [M+Na]+, 731.2 [M2 + Na]+. 
HRMS (m/z) [M+H]+ for C20H23N2O2S calculated = 355.0657, 
measured = 355.0657. 
4.8. 2-(2'-Methoxyphenyl)-5-methylthio-7-(2'-naphthyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene 9h 
Obtained as per the method for compound 9a as a clear 
yellow oil (72 mg, 44%) from 2-methylthio-4-(2'-naphthyl)-1-
azetine (8b)18 (100 mg, 0.440 mmol) and 4-
methoxybenzohydroximoyl chloride (19e) (100 mg, 0.539 
mmol); Rf = 0.3 (PE 40-60  ºC / EtOAc: 10/1). 
IR υmax (cm-1) 2928 (w), 1608 (s), 1511 (s), 1404 (m), 1349 
(m), 1256 (s), 1172 (m), 1028 (m), 836 (m). 
1H NMR:  (500 MHz, CDCl3) 7.98 (2H, d, J=8.8 Hz, 4-
MeOAr), 7.94-7.85 (2H, m, naphth), 7.57-7.47 (3H, m, naphth), 
7.0-6.95 (2H, m, naphth), 6.80 (2H, d, J=8.8 Hz, 4-MeOAr), 5.0 
(1H, dd, J=5.5 and 9.5 Hz, naphthCH), 3.77 (3H, s, OCH3), 3.74 
(1H, dd, J=9.5 and 13.5 Hz, naphthCHCH2), 2.82 (1H, dd, 
J=13.5 and 5.5 Hz, naphthCHCH2), 2.30 (3H, s, SCH3). 
13C NMR  (125 MHz, CDCl3) 161.8 (N=C-N), 138.1 (C, Ar), 
133.3 (C, Ar), 133.2 (C, Ar), 130.2 (C, Ar), 130.0 (CH, Ar), 
129.0 (CH, Ar), 128.4 (CH, Ar), 128.1 (CH, Ar), 126.8 (CH, Ar), 
126.4 (CH, Ar), 125.2 (CH, Ar), 123.9 (CH, Ar), 116. 8 (CH, 
Ar), 114.4 (C, Ar), 111.3 (C-SMe), 66.6 (CH), 55.3 (OCH3), 44.7 
(CH2), 10.4 (SCH3). 
HRMS (m/z) [M + Na]+ for C22H20N2NaO2S calculated 
399.1138 measured 399.1142.  
4.9. 3-(2-Azidophenyl)-5-ethylthio-1,2,4-oxadiazole 10a 
2-(2-Azidophenyl)-5-ethylthio-7-phenyl-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene (9a) (100 mg, 0.284 mmol) 
was dissolved in toluene (5 mL) and heated at reflux for 47 h. 
The solvent was removed in vacuo and the crude product was 
purified by gravity silica chromatography (Rf = 0.4; PE 40-60 ºC 
/ EtOAc : 7/1) to yield the title product as an orange oil (36 mg, 
51%). 
IR υmax (cm-1) 2930 (w), 2130-2100 (s), 1582 (m), 1520 (m), 
1505 (m), 1470 (m), 1339 (s), 1304 (m), 1271 (m), 1187 (m), 750 
(m). 
1H NMR δ (400 MHz, CDCl3) 7.99 (1H, dd, J=7.7 and 1.6 Hz, 
ArH), 7.55 (1H, ddd, J=8.1, 7.4 and 1.6 Hz, ArH), 7.27 (1H, dd, 
J=8.1 and 0.8 Hz, ArH), 7.19 (1H, td, J=7.7 and 0.8 Hz, ArH), 
3.34 (2H, q, J=7.4 Hz, SCH2CH3), 1.54 (3H, t, J=7.4 Hz, 
SCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 177.6 (S-C=N), 166.7 (N-
C=N), 138.9 (C, Ar), 132.1 (CH, Ar), 131.6 (CH, Ar), 124.9 
(CH, Ar), 119.3 (CH, Ar), 118.2 (C, Ar), 27.3 (SCH2CH3), 14.8 
(SCH2CH3). 
MS (m/z) 248.1 [M+H]+, 270.0 [M+Na]+, 517.1 [M2+Na]+. 
HRMS (m/z) [M+H]+ for C10H10N5OS calculated 248.0601 
measured 248.0603. 
4.10. 3-(2-Azidophenyl)-5-methylthio-1,2,4-oxadiazole 10b 
Obtained as a clear, yellow oil (41 mg, 68% yield) as per the 
method for compound 10a from 2-(2-azidophenyl)-7-(2'-
naphthyl)-5-methylthio-4-oxa-1,3-diazabicyclo[3.2.0]-hept-2-ene 
(9b, 100 mg) after silica chromatography (Rf = 0.2; eluent: 
petroleum ether: ethyl acetate, 16:1). 
IR υmax (cm-1) 2966 (w), 2128 (s), 1597 (m), 1578 (m), 1501 
(m), 1300 (m), 750 (m). 
1H NMR: H (500 MHz, CDCl3) 7.97 (1H, dd, J=2.0 and 8.0 
Hz, ArH), 7.55-7.45 (1H, m, ArH), 7.37 (1H, dd, J=2.0 and 8.0 
Hz, ArH), 7.27-7.22 (1H, m, ArH), 2.73 (3H, s, SCH3). 
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13C NMR  (125 MHz, CDCl3) 178.0 (C, oxadiazole), 166.7 
(C, oxadiazole), 138.8 (C, Ar), 132.1 (CH, Ar), 131.0 (CH, Ar), 
124.9 (CH, Ar), 119.3 (CH, Ar), 118.9 (C, Ar), 15.3 (SCH3).  
HRMS (m/z) [M+Na]+ for C9H7N5NaOS calculated 256.0264 
measured 256.0273. 
4.11. 3-(Phenyl)-5-ethylthio-1,2,4-oxadiazole 10c 
Obtained as a clear, yellow oil (72 mg, 83% yield) as per the 
method for compound 10a from 2,7-diphenyl-5-ethylthio-4-oxa-
1,3-diazabicyclo[3.2.0]-hept-2-ene (9c, 130 mg) after silica 
chromatography (Rf = 0.2; eluent: petroleum ether: ethyl acetate, 
16:1). 
IR υmax (cm-1) 2935 (m), 1544 (m), 1522 (s), 1474 (m), 1359 
(m), 1266 (s), 1195 (m).   
1H NMR δ (400 MHz, CDCl3) 7.27-7.33 (3H, m, Ar-H), 7.23-
7.13 (2H, m, Ar-H), 3.38 (2H, q, J=7.5 Hz, SCH2), 1.56 (3H, t, 
J=7.5 Hz, CH3).   
13C NMR δ (100 MHz, CDCl3) 176.9 (C), 137.8 (C), 130.9 
(CH, Ar), 128.9 (CH, Ar), 126.1 (C), 125.3 (CH, Ar), 28.9 (CH2), 
21.4 (CH3).         
HRMS (m/z) [M+H]+ for C10H10N2OS calculated = 207.1404, 
measured = 207.1407.  
4.12. 3-(4-Methoxyphenyl)-5-methylthio-1,2,4-oxadiazole 10e/f/h 
Obtained as a clear, yellow oil (45 mg, 88% yield),  (52 mg, 
82% yield) and (34 mg, 87% yield), as per the method for 
compound 10a, from 2-(4'-methoxyphenyl)-5-methylthio-7-
phenyl-4,1,3-oxadiazabicyclo[3.2.0]hept-2-ene (9e, 80 mg) or 2-
(4'-methoxyphenyl)-5-methylthio-7-(4'-tolyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene (9f, 100 mg), or 2-(4'-
methoxyphenyl)-5-methylthio-7-(2'-naphthyl)-4,1,3-
oxadiazabicyclo[3.2.0]hept-2-ene (9h, 70 mg), respectively, after 
silica chromatography (eluent: petroleum ether: ethyl acetate, 
16:1); Rf = 0.5 (PE 40-60 ºC / EtOAc : 10/1). 
IR υmax (cm-1) 2919 (m), 1611 (s), 1509 (s), 1466 (m), 1422 
(m), 1346 (m), 1297 (m), 1250 (s), 1198 (m), 1117 (m), 1027 
(m), 833 (s), 758 (s). 
1H NMR:   H (500 MHz, CDCl3) 7.99 (2H, d, J=8.0, ArH), 
6.98 (2H, d, J=8.0, ArH), 3.85 (3H, s, OMe), 2.78 (3H, s, SMe). 
 13C NMR: C (125 MHz, CDCl3) 178.1 (C, oxadiazole), 168.3 
(C, oxadiazole), 162.0 (C, Ar), 129.1 (CH, Ar), 119.0 (C, Ar), 
114.2 (CH, Ar), 55.4 (O-CH3), 14.2 (S-CH3). 
HRMS (m/z) [M+Na]+ for C10H10N2NaO2S calculated = 
245.0355, measured = 245.0350. 
4.13. 3-(4-Methoxyphenyl)-5-ethylthio-1,2,4-oxadiazole 10g 
Obtained as a clear, yellow oil (40 mg, 81% yield) as per the 
method for compound 10a from 2-(4'-methoxyphenyl)-5-
ethylthio-7-(4'-tolyl)-4,1,3-oxadiazabicyclo[3.2.0]hept-2-ene (9g, 
80 mg) after silica chromatography (eluent: petroleum ether: 
ethyl acetate, 16:1); Rf = 0.5 (PE 40-60 ºC / EtOAc : 10/1). 
IR υmax (cm-1) 2920 (w), 1611 (s), 1505 (s), 1420 (m), 1348 
(s), 1299 (m), 1250 (s), 1171 (m), 1028 (m), 838 (m), 753 (m). 
1H NMR: H (500 MHz, CDCl3): 7.98 (2H, d, J=8.1 Hz, ArH), 
6.96 (2H, d, J=8.1 Hz, ArH), 3.86 (3H, s, OMe), 3.32 (2H, q, 
J=7.9 Hz, CH2CH3), 1.52 (3H, t, J=7.9 Hz, CH2CH3). 
13C NMR  (125 MHz, CDCl3): 177.6 (C, oxadiazole), 168.3 
(C, oxadiazole), 162.0 (C, Ar), 129.0 (CH, Ar), 119.0 (C, Ar), 
114.2 (CH, Ar), 55.4 (O-CH3), 27.3 (S-CH2), 14.8 (S-CH2CH3). 
  MS (m/z) 259.0 [M+Na]+, 731.2 [M2 + Na]+. 
HRMS (m/z) [M+Na]+ for C11H12N2NaO2S calculated = 
259.0511, measured = 259.0518. 
4.14. Synthesis of 1,2,3-triazole 10i:  Reaction of 2-(2-
azidophenyl)-5-ethylthio-7-phenyl-4,1,3-oxadiazabicyclo[3.2.0]-
hept-2-ene with DMAD 
2-(2-Azidophenyl)-5-ethylthio-7-phenyl-4,1,3-oxadiaza 
bicyclo[3.2.0]hept-2-ene (9a) (110 mg, 0.313 mmol) and 
dimethylacetylene dicarboxylate (DMAD) (42 μL, 49 mg, 0.34 
mmol, 1 eq.) were dissolved in toluene (5 mL) and the solution 
was heated at reflux under nitrogen overnight. The solvent was 
removed in vacuo to give the crude product as an orange oil, 
which was purified by gravity silica chromatography (Rf = 0.3; 
PE 40-60 ºC/EtOAc: 10/1) to give the triazole derivative 10i as a 
yellow oil (50 mg, 41%). 
IR υmax (cm-1) 2954 (w), 1735 (s, C=O), 1557 (w), 1507 (m), 
1474 (m), 1448 (m), 1358 (s), 1290 (m), 1232 (m), 1181 (m), 
1105 (m), 1078 (m), 1004 (w), 963 (w), 826 (w), 809 (w), 777 
(w), 758 (m), 669 (w). 
1H NMR δ (500 MHz, CDCl3) 8.25 (1H, dd, J=7.1 and 2.2 Hz, 
ArH), 7.68 – 7.74 (2H, m, ArH), 7.54 (1H, dd, J=7.4 and 1.6 Hz, 
ArH), 4.02 (3H, s, CO2Me), 3.76 (3H, s, CO2Me), 3.09 (2H, q, 
J=7.4 Hz, SCH2CH3), 1.36 (3H, t, J=7.4 Hz, SCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 178.9 (EtS-C=N), 165.5 (N-
C=N), 160.4 (C=O), 158.1 (C=O), 139.1 (C, Ar), 133.8 (C=C), 
133.1 (C=C), 131.6 (CH, Ar), 131.4 (CH, Ar), 130.1 (CH, Ar), 
128.7 (CH, Ar), 124.2 (C, Ar), 53.3 (CO2CH3), 52.7 (CO2CH3), 
27.4 (SCH2CH3), 14.5 (SCH2CH3). 
MS (m/z) 390.1 [M+H]+, 412.1 [M+Na]+, 779.2 [M2+H]+, 
801.1 [M2+Na]+. 
HRMS (m/z) [M+H]+ for C16H16N5O5S calculated 390.0867 
measured 390.0867. 
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